Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
The purpose of this study is to explore the detection of circulating tumor DNA, soluble immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
Checked against the public recordLast updated Jul 21, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Mayo Clinic
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced (non-resectable) malignancy in the thorax * Age \>18 years old * Willing and able to provide consent * No prior history of neoadjuvant therapy Exclusion Criteria: * Age \<18 years old * Unable to provide consent * Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential iatrogenic anemia)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo ClinicRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 21, 2021. Always confirm current availability with the study team.